Skip to main content

CASE REPORT article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1431422
This article is part of the Research Topic The Molecular Mechanism in Anti-tumor Therapy Resistance View all 11 articles

Disitamab Vedotin combined with Pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report

Provisionally accepted
Jianxin Chen Jianxin Chen 1*Jian Wang Jian Wang 2Qinhong Zheng Qinhong Zheng 1
  • 1 The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People′s Hospital, Quzhou, China
  • 2 Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    Background: Human epidermal growth factor receptor 2 amplification (Her-2) has been identified in approximately 3% patients with metastatic colorectal cancer (mCRC). Owing to the lacking of established anti-ERBB2 therapeutic approaches, mCRC patients with Her-2 amplification rarely receive targeted treatments. Moreover, conventional chemotherapy regimens are not ideal for these patients, leaving options in the advanced stage limited to best supportive care or participation in clinical drug trials.Case presentation: This report presents a case of a Her-2-amplified refractory mCRC patient treated with a salvage regimen combining Disitamab Vedotin and pyrotinib, resulting in a partial response and progression-free survival of 6 months, which is still ongoing.Conclusions: This case study suggests that the anti-Her-2 regimen involving Disitamab Vedotin and pyrotinib may offer a potential salvage treatment option for Her-2-amplified mCRC patients. However, further validation in larger cohorts is necessary.

    Keywords: Disitamab vedotin, Pyrotinib, refractory metastatic colorectal cancer, HER-2 amplification, case report

    Received: 11 May 2024; Accepted: 31 Jan 2025.

    Copyright: © 2025 Chen, Wang and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jianxin Chen, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People′s Hospital, Quzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.